"Interleukin-17" - Books

Result Filters

Results: 1 to 20 of 72 books (239 items)

<< First< Prev

Page of 4

Next >Last >>

Select item 44036681.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Top results in this book Table of Contents

Select item 44650642.

Autoimmunity: From Bench to Bedside [Internet].

Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors.

Bogota (Colombia): El Rosario University Press; 2013 Jul 18.

Top results in this book Table of Contents

Select item 55233603.

Upadacitinib (Rinvoq): CADTH Reimbursement Review: Therapeutic area: Ankylosing spondylitis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Aug.

Top results in this book Table of Contents

Select item 16686904.

Holland-Frei Cancer Medicine. 6th edition.

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.

Hamilton (ON): BC Decker; 2003.

Top results in this book Table of Contents

Select item 53637605.

Clinical Review Report: Tildrakizumab (Ilumya): (Sun Pharma Global FZE): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Aug.

Top results in this book Table of Contents

Select item 14152806.

Madame Curie Bioscience Database [Internet].

Austin (TX): Landes Bioscience; 2000-2013.

Top results in this book Table of Contents

Select item 34012947.

Endotext [Internet].

Feingold KR, Anawalt B, Blackman MR, et al., editors.

South Dartmouth (MA): MDText.com, Inc.; 2000-.

Top results in this book Table of Contents

Select item 14589848.

GeneReviews® [Internet].

Adam MP, Feldman J, Mirzaa GM, et al., editors.

Seattle (WA): University of Washington, Seattle; 1993-2024.

Top results in this book Table of Contents

Select item 54877249.

Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with active ankylosing spondylitis who have had an inadequate response to a biologic disease-modifying antirheumatic drug or when use of those therapies is inadvisable. Upadacitinib may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.

Top results in this book Table of Contents

Select item 464581010.

Signaling Mechanisms Regulating T Cell Diversity and Function.

Soboloff J, Kappes DJ, editors.

Boca Raton (FL): CRC Press/Taylor & Francis; 2018.

Top results in this book Table of Contents

Select item 564454811.

Bimekizumab (Bimzelx): CADTH Reimbursement Review: Therapeutic area: Psoriasis, moderate to severe plaque [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 May.

Top results in this book Table of Contents

Select item 564999212.

Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.

Top results in this book Table of Contents

Select item 553901413.

Deucravacitinib (Sotyktu): CADTH Reimbursement Review: Therapeutic area: Psoriasis, moderate to severe plaque [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct.

Top results in this book Table of Contents

Select item 423716014.

Vitamin D for the Treatment or Prevention of Multiple Sclerosis: A Review of the Clinical Effectiveness [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Mar 10.

Top results in this book Table of Contents

Select item 307166815.

Microbial Ecology in States of Health and Disease: Workshop Summary.

Forum on Microbial Health; Board on Global Health; Institute of Medicine.

Washington (DC): National Academies Press (US); 2014 Feb 18.

Top results in this book Table of Contents

Select item 557379416.

$Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn’s disease: the ASTIClite RCT.$

Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn’s disease: the ASTIClite RCT.

Lindsay JO, Hind D, Swaby L, et al.

Southampton (UK): National Institute for Health and Care Research; 2024 Jan. (Efficacy and Mechanism Evaluation, No. 11.03.)

Top results in this book Table of Contents

Select item 552427017.

Risankizumab (Skyrizi): CADTH Reimbursement Review: Therapeutic area: Crohn disease [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Aug.

Top results in this book Table of Contents

Select item 481220618.

Clinical Review Report: Risankizumab (Skyrizi): (AbbVie): Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.

Top results in this book Table of Contents

Select item 531740419.

Understanding the Role of the Immune System in Improving Tissue Regeneration: Proceedings of a Workshop.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Regenerative Medicine; Nicholson A, Schumm SN, Beachy SH, editors.

Washington (DC): National Academies Press (US); 2022 Apr 21.

Top results in this book Table of Contents

Select item 235805220.

Probe Reports from the NIH Molecular Libraries Program [Internet].

Bethesda (MD): National Center for Biotechnology Information (US); 2010-.

Top results in this book Table of Contents

<< First< Prev

Page of 4

Next >Last >>

Supplemental Content

Images search in Bookshelf

FIGURE A11-1Mechanisms of Fungal Sensing and Control

The β-glucan on the budding yeast forms of candida bind to dectin-1 on epithelial cells and phagocytes, leading to activation of the CARD9 signaling complex (along with Bcl-10–MALT1) (Panel A). This in turn produces cytokines that help drive CD4+ T lymphocytes toward the Th17 phenotype, a STAT3-dependent process. Th17 lymphocytes elaborate interleukin-17 (augmenting neutrophil production and recruitment) and interleukin-22, which are synergic in the STAT3-dependent production of antimicrobial peptides by epithelial cells. The generation of superoxide by the phagocytic NADPH oxidase system is crucial for the killing of filamentous molds such as aspergillus (Panel B). Interactions between macrophages and lymphocytes are required for the control of intracellular infections such as the dimorphic fungi. In response to fungal infection, macrophages release interleukin-12, which acts on its cognate receptor on T lymphocytes and natural killer (NK) lymphocytes. Interleukin-12–stimulated lymphocytes release interferon-γ, which acts on macrophages through STAT1 to kill intracellular fungi. Interferon-γ also augments tumor necrosis factor α (TNF-α), which acts in part through the nuclear factor κB (NF-κB) to kill fungi and drive inflammatory responses. Molecules with identified mutations relevant to fungal susceptibility are shown in red.

Contributed Manuscripts.

Institute of Medicine (US) Forum on Microbial Threats. Fungal Diseases: An Emerging Threat to Human, Animal, and Plant Health: Workshop Summary. Washington (DC): National Academies Press (US); 2011.